Allergan Wins First Approval for Short-Acting Neurotoxin in Canada
The product is the first botulinum toxin type E approved for aesthetic use and is designed to deliver faster onset and shorter-lasting results than traditional neurotoxins.
The product is the first botulinum toxin type E approved for aesthetic use and is designed to deliver faster onset and shorter-lasting results than traditional neurotoxins.
The facility features a dedicated training space for healthcare professionals and supports the company’s long-term investment in the dermatology market.